The beautiful times have just started for this cmpany. With potential nasal caclcitonin sales annually of $20 million if they get their expected share of the Miacalcin market, this stock is undervalued using normal p/e multiples. If the company gets its phase 2 milestone payment around $10 million, we could easily see a $1-$1.50 move in the price. Once a stock hits the $5 target, it becomes legitamized, becomes marginable (after listing on Nasdaq) and is followed and eligible for investment by major institutions and big investors. I hope to see $7 in the near future.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.